298 related articles for article (PubMed ID: 16151586)
41. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Kern W; Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T
Haematologica; 2004 May; 89(5):528-40. PubMed ID: 15136215
[TBL] [Abstract][Full Text] [Related]
42. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
43. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
44. The approach to the elderly patient with acute myeloid leukemia.
Stone RM; Mayer RJ
Hematol Oncol Clin North Am; 1993 Feb; 7(1):65-79. PubMed ID: 7680642
[TBL] [Abstract][Full Text] [Related]
45. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
46. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
47. Acute myeloid leukemia in the elderly:--159 Nagoya case studies--Nagoya Cooperative Study Group for Elderly Leukemia.
Nagura E; Minami S; Nagata K; Morishita Y; Takeyama H; Sao H; Suzuki H; Naoe T; Yokomaku S; Mizuno H; Murase T; Hirabayashi N; Takeo T; Tanimoto M; Kawashima K; Saito H
Nagoya J Med Sci; 1999 Nov; 62(3-4):135-44. PubMed ID: 10689875
[TBL] [Abstract][Full Text] [Related]
48. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
50. [Therapy of disseminated intravascular coagulation in acute promyelocytic leukemias. Apropos of 19 cases].
Rodríguez Gómez M; López Fernández MF; Batlle J
Sangre (Barc); 1993 Dec; 38(6):449-53. PubMed ID: 8171380
[TBL] [Abstract][Full Text] [Related]
51. [Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
Indrák K; Hubácek J; Mayer J; Voglová J; Jarosová M; Krahulová M; Malý J; Faber E; Penka M; Kmonícek M; Jebavý L; Szotkowski T; Knotková R; Hlusí A; Zapletalová J
Vnitr Lek; 2001 Sep; 47 Suppl 1():48-56. PubMed ID: 11693063
[TBL] [Abstract][Full Text] [Related]
52. [Acute myeloid leukemia in the adult. Results of the National Antineoplastic Drug Protocol at the Hospital del Salvador, 1990-1998].
Puga BL; Cabrera ME; Undurraga MS; Etcheverry R; Vacarezza R; Ducach G; Toledo H
Rev Med Chil; 2000 Nov; 128(11):1191-8. PubMed ID: 11347505
[TBL] [Abstract][Full Text] [Related]
53. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
[TBL] [Abstract][Full Text] [Related]
54. Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia.
Lee JH; Choi SJ; Lee JH; Park JH; Kim H; Joo YD; Lee WS; Zang DY; Kim HJ; Lee KH;
Ann Hematol; 2006 Jun; 85(6):357-65. PubMed ID: 16575580
[TBL] [Abstract][Full Text] [Related]
55. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Matsouka P; Pagoni M; Zikos P; Giannakoulas N; Apostolidis I; Asprogeraka T; Arvanitopoulou E; Spanoudakis E; Kotsianidis I; Tsatalas K; Papaioannou M; Marinakis T; Skandali A; Viniou N; Yataganas X; Bakiri M
Ann Hematol; 2006 Apr; 85(4):250-6. PubMed ID: 16416114
[TBL] [Abstract][Full Text] [Related]
56. Acute myeloid leukaemia (AML): treatment of the older patient.
Büchner T; Hiddemann W; Schoch C; Haferlach T; Sauerland MC; Heinecke A
Best Pract Res Clin Haematol; 2001 Mar; 14(1):139-51. PubMed ID: 11355928
[TBL] [Abstract][Full Text] [Related]
57. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
[TBL] [Abstract][Full Text] [Related]
58. Treatment of older patients with AML.
Büchner T; Berdel WE; Wörmann B; Schoch C; Haferlach T; Schnittger S; Kern W; Aul C; Lengfelder E; Schumacher A; Reichle A; Staib P; Balleisen L; Eimermacher H; Grüneisen A; Rasche H; Sauerland MC; Heinecke A; Mesters RM; Serve HL; Kienast J; Hiddemann W
Crit Rev Oncol Hematol; 2005 Nov; 56(2):247-59. PubMed ID: 16246568
[TBL] [Abstract][Full Text] [Related]
59. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
60. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
